Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Background: The synergistic effects of antiangiogenic inhibitor bevacizumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) therapy were encouraging in patients with EGFR-mutant advanced NSCLC, though some controversy remains. The specific subgroup of patients who might be...

Full description

Bibliographic Details
Main Authors: Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, Shiyun He, Hongying Liao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
EGFR
NSCLC
bevacizumab
EGFR-TKI
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1238579/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1238579/full

Similar Items